These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16790517)

  • 1. Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group.
    Fountzilas G; Papakostas P; Dafni U; Makatsoris T; Karina M; Kalogera-Fountzila A; Maniadakis N; Aravantinos G; Syrigos K; Bamias A; Christodoulou C; Economopoulos T; Kalofonos H; Nikolaou A; Angouridakis N; Stathopoulos G; Bafaloukos D; Pavlidis N; Daniilidis J
    Ann Oncol; 2006 Oct; 17(10):1560-7. PubMed ID: 16790517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group.
    Fountzilas G; Stathopoulos G; Nicolaides C; Kalogera-Fountzila A; Kalofonos H; Nikolaou A; Bacoyiannis C; Samantas E; Papadimitriou C; Kosmidis P; Daniilidis J; Pavlidis N
    Ann Oncol; 1999 Apr; 10(4):475-8. PubMed ID: 10370793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
    Edwards SJ; Barton S; Thurgar E; Trevor N
    Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
    Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
    Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
    Janinis J; Stathopoulos GP; Nikolaidis P; Kalofonos HP; Kalogera-Fountzila A; Samantas E; Aravantinos G; Anagnostopoulos A; Tolis C; Makatsoris T; Rigatos SK; Bafaloukos D; Dimopoulos MA; Daniilidis J; Fountzilas G
    Anticancer Drugs; 2004 Jun; 15(5):479-87. PubMed ID: 15166622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
    Tas F; Guney N; Derin D; Aydiner A; Topuz E
    Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.
    Bafaloukos D; Linardou H; Aravantinos G; Papadimitriou C; Bamias A; Fountzilas G; Kalofonos HP; Kosmidis P; Timotheadou E; Makatsoris T; Samantas E; Briasoulis E; Christodoulou C; Papakostas P; Pectasides D; Dimopoulos AM
    BMC Med; 2010 Jan; 8():3. PubMed ID: 20055981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
    Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
    Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
    Poh SB; Bai LY; Chen PM
    Am J Clin Oncol; 2005 Dec; 28(6):540-6. PubMed ID: 16317261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG).
    Kosmidis PA; Fountzilas G; Eleftheraki AG; Kalofonos HP; Pentheroudakis G; Skarlos D; Dimopoulos MA; Bafaloukos D; Pectasides D; Samantas E; Boukovinas J; Lambaki S; Katirtzoglou N; Bakogiannis C; Syrigos KN
    Ann Oncol; 2011 Apr; 22(4):827-834. PubMed ID: 20880999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
    Fountzilas G; Christodoulou C; Tsavdaridis D; Kalogera-Fountzila A; Aravantinos G; Razis E; Kalofonos HP; Papakostas P; Karina M; Gogas H; Skarlos D
    Cancer Invest; 2004; 22(5):655-62. PubMed ID: 15581045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine and paclitaxel in metastatic or recurrent squamous cell carcinoma of the head and neck: a phase I-II study.
    Stier S; Koll C; Neuhaus T; Fronhoffs S; Forkert R; Tuohimaa A; Vetter H; Ko Y
    Anticancer Drugs; 2005 Nov; 16(10):1115-21. PubMed ID: 16222154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of pegylated liposomal doxorubicin (Caelyx) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer.
    Ulrich-Pur H; Kornek GV; Haider K; Kwasny W; Payrits T; Dworan N; Vormittag L; Depisch D; Lang F; Scheithauer W
    Acta Oncol; 2007; 46(2):208-13. PubMed ID: 17453371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329.
    Malhotra B; Moon J; Kucuk O; Clark JI; Urba SG; Wolf GT; Worden FP
    Head Neck; 2014 Dec; 36(12):1712-7. PubMed ID: 24166832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
    Pectasides D; Xiros N; Papaxoinis G; Aravantinos G; Sykiotis C; Pectasides E; Psyrri A; Koumarianou A; Gaglia A; Gouveris P; Economopoulos T
    Gynecol Oncol; 2008 Jan; 108(1):47-52. PubMed ID: 17915300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.
    Mirza MR; Lund B; Lindegaard JC; Keldsen N; Mellemgaard A; Christensen RD; Bertelsen K
    Gynecol Oncol; 2010 Oct; 119(1):26-31. PubMed ID: 20638711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
    Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
    Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.
    Pectasides D; Pectasides E; Papaxoinis G; Psyrri A; Pliarchopoulou K; Koumarianou A; Macheras A; Athanasas G; Xiros N; Economopoulos T
    Gynecol Oncol; 2010 Jul; 118(1):52-7. PubMed ID: 20406710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
    Giuliani J; Bonetti A
    Int J Gynecol Cancer; 2017 Nov; 27(9):1872-1876. PubMed ID: 28976446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
    Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
    Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.